Acute respiratory failure is the sudden inability of the lungs to perform adequate gas exchange, resulting in dangerously low oxygen levels, a dangerous buildup of carbon dioxide, or both. Clinically, it is defined by specific blood gas thresholds: an arterial oxygen level below 60 mm Hg or an oxygen saturation below 88% for the hypoxemic type, and an arterial carbon dioxide level at or above 45 mm Hg with a blood pH below 7.35 for the hypercapnic type.1PubMed Central. Diagnosis and Management of Acute Respiratory Failure The word “acute” distinguishes it from chronic respiratory failure, where the body has had time to compensate. What makes the acute form dangerous is precisely that speed: the compensatory mechanisms haven’t kicked in yet, and vital organs can suffer damage within minutes to hours.
Two Types and What They Mean
Acute respiratory failure splits into two categories based on which side of gas exchange has failed. Type 1, or hypoxemic respiratory failure, means the lungs cannot get enough oxygen into the blood. Type 2, or hypercapnic respiratory failure, means the lungs cannot clear enough carbon dioxide. Some patients have both problems at once, but the distinction matters because the underlying mechanisms and treatments differ.
In Type 1, the hallmark is a partial pressure of oxygen (PaO2) below 60 mm Hg while breathing room air. The carbon dioxide level may be normal or even low because the body is breathing faster to compensate. This form commonly shows up in pneumonia, pulmonary embolism, acute respiratory distress syndrome (ARDS), and severe asthma attacks. The root problem is usually that parts of the lung are receiving blood flow but not enough air, or that fluid or inflammation is blocking the transfer of oxygen across the lung’s thin membranes.
In Type 2, the defining feature is a PaCO2 at or above 45 mm Hg combined with an acidic blood pH below 7.35. The pH criterion is crucial because some people walk around with elevated carbon dioxide levels for years due to chronic lung disease, and their blood chemistry has adjusted. In the acute form, the body hasn’t had time to buffer that acid, so the blood becomes dangerously acidic. Type 2 failure often stems from problems outside the lungs themselves: drug overdoses that suppress the brainstem’s drive to breathe, neuromuscular diseases like myasthenia gravis, chest wall injuries, or severe flare-ups of chronic obstructive pulmonary disease (COPD).2European Respiratory Journal. Respiratory failure
The Mechanisms Behind Low Oxygen
When oxygen levels plummet, the explanation usually traces back to one of a handful of physiological breakdowns. The most common is a ventilation-perfusion mismatch, where some regions of the lung receive blood but not enough air, or air but not enough blood. Healthy lungs match airflow and blood flow in each region with remarkable precision. When that matching breaks down, oxygen transfer becomes inefficient.
A more extreme version of this mismatch is called a shunt. In a true shunt, blood passes through the lungs without encountering any air at all, either because the air sacs are completely collapsed or flooded, or because of a structural defect that lets blood bypass the lungs entirely. Shunts are particularly stubborn because giving a patient extra oxygen doesn’t help much: the blood flowing past non-functioning lung tissue never touches the supplemental oxygen.3PubMed Central. Pulmonary Shunt in Critical Care: A Comprehensive Review of Pathophysiology, Diagnosis, and Management Strategies In conditions like ARDS, both shunting and ventilation-perfusion mismatch occur simultaneously. Collapsed or fluid-filled lung units create shunts that drive oxygen levels down, while non-perfused but ventilated areas increase dead space, which can push carbon dioxide levels up.4PubMed Central. Pathophysiology and Clinical Meaning of Ventilation-Perfusion Mismatch in the Acute Respiratory Distress Syndrome
Other causes of low oxygen include diffusion impairment, where the barrier between air and blood is thickened by disease (as in pulmonary fibrosis), and simply breathing air with too little oxygen, such as at extreme altitudes. Hypoventilation, where a person isn’t moving enough air in and out, causes both low oxygen and high carbon dioxide. This is the mechanism at work when someone overdoses on opioids: the brain stops telling the muscles to breathe fast enough or deeply enough.
How Acute Differs from Chronic Respiratory Failure
The word “acute” does more work than it might seem. A person with severe COPD may live for years with a PaCO2 of 55 mm Hg, well above the 45 mm Hg threshold. Their kidneys have slowly compensated by retaining bicarbonate to buffer the acid, so their blood pH stays near normal. That’s chronic respiratory failure. It’s manageable and often treated at home with supplemental oxygen or nighttime ventilation.
Acute respiratory failure, by contrast, develops over minutes to days and outpaces the body’s ability to compensate. The pH drops. Organs start to struggle. A third category, acute-on-chronic respiratory failure, describes what happens when someone with an existing chronic condition gets hit with an additional insult, like a chest infection, that tips them over the edge. Distinguishing these three scenarios is possible by looking at the acid-base balance in the blood.5Medicine. Respiratory failure A COPD patient with a pH of 7.25 and a PaCO2 of 80 mm Hg is in acute-on-chronic failure: the chronic baseline has worsened sharply, and the kidneys haven’t caught up.
This distinction has practical consequences. In acute-on-chronic Type 2 failure from a COPD flare-up, non-invasive ventilation delivered through a face mask can be highly effective. One study of COPD patients receiving non-invasive ventilation for 12 hours found that about 97% improved enough to bring their pH above 7.35 and their carbon dioxide below 60 mm Hg.6The Professional Medical Journal. Outcome of non-invasive ventilation (NIV) among patients with type II respiratory failure due to acute exacerbation of chronic obstructive pulmonary disease (COPD) Pure acute failure in someone without pre-existing lung disease can be harder to manage because the lungs have no reserve capacity to fall back on.
How Clinicians Make the Diagnosis
The gold standard for confirming acute respiratory failure is an arterial blood gas (ABG) sample, drawn from an artery rather than a vein. This gives precise measurements of oxygen, carbon dioxide, and pH. But an ABG is invasive, requires training, and isn’t always immediately available, especially outside large hospitals. In many settings, pulse oximetry has become the first-line tool for detecting hypoxemia because it’s painless and gives continuous readings.
Pulse oximetry measures the oxygen saturation of hemoglobin (SpO2) through a fingertip sensor. It’s fast and ubiquitous, and the ratio of SpO2 to the fraction of inspired oxygen (the SpO2/FiO2 ratio) has gained traction as a non-invasive stand-in for the arterial-based PaO2/FiO2 ratio, particularly in resource-limited settings where arterial blood gas analyzers are scarce.7PubMed Central. Non-invasive SpO2/FiO2 ratio (SFR) as surrogate for PaO2/FiO2 ratio (PFR): A scoping review The updated global definition of ARDS now formally incorporates pulse oximetry-based criteria alongside the traditional arterial blood gas thresholds, a significant shift that makes the diagnosis accessible in hospitals that lack blood gas machines.8PubMed Central. A New Global Definition of Acute Respiratory Distress Syndrome
Imaging plays an important supporting role. Chest X-rays are standard, but bedside lung ultrasound has emerged as a faster and more accurate alternative in emergency settings. One study comparing the two found that ultrasound correctly identified the cause of acute respiratory failure about 84% of the time, compared with 43% for chest X-ray alone.9Jornal Brasileiro de Pneumologia. Diagnostic accuracy of the Bedside Lung Ultrasound in Emergency protocol for the diagnosis of acute respiratory failure in spontaneously breathing patients Ultrasound is portable, doesn’t involve radiation, and can be done at the bedside in seconds, which makes it especially useful in emergency departments and ICUs.
ARDS as a Severe Subset
Acute respiratory distress syndrome sits within the broader category of acute hypoxemic respiratory failure but carries its own formal definition and criteria. It represents the severe end of the spectrum, characterized by widespread inflammation in the lungs, fluid leaking into the air sacs, and stiff, hard-to-ventilate lungs. The causes range from pneumonia and sepsis to trauma, aspiration, and pancreatitis.
For decades, ARDS was defined by the Berlin criteria published in 2012, which required bilateral lung opacities on chest imaging, respiratory failure not fully explained by heart failure, and a PaO2/FiO2 ratio below 300. A large international study across 50 countries found that ARDS accounted for about 10% of all ICU admissions and nearly a quarter of patients requiring mechanical ventilation.10JAMA. Epidemiology, Patterns of Care, and Mortality for Patients With Acute Respiratory Distress Syndrome in Intensive Care Units in 50 Countries Hospital mortality in that study was 40%, underscoring why the condition demands early recognition.
In 2023, an international panel proposed a new “global” definition of ARDS that builds on the Berlin criteria but makes several practical updates. The new definition allows the use of pulse oximetry instead of arterial blood gases, accepts lung ultrasound alongside chest X-ray and CT for identifying bilateral opacities, and formally includes patients on high-flow nasal oxygen rather than requiring invasive mechanical ventilation for diagnosis.11PubMed Central. A New Global Definition of Acute Respiratory Distress Syndrome These changes are partly pragmatic: many patients in low-resource hospitals never receive an arterial blood draw or a CT scan, so the previous criteria missed a large fraction of ARDS cases around the world. The expanded definition also reflects how clinical practice has evolved, with high-flow nasal oxygen now widely used as a first-line treatment for severe hypoxemia before intubation is considered.12American Journal of Respiratory and Critical Care Medicine. Mapping Berlin in the Global Definition of ARDS: Overlap and Progression Between Berlin and Global Definitions
High-Flow Nasal Oxygen and Predicting Who Will Need More
High-flow nasal cannula (HFNC) therapy has reshaped how clinicians manage acute hypoxemic respiratory failure in its early stages. The device delivers heated, humidified oxygen at flow rates far beyond what a standard nasal cannula provides. Increasing the flow rate progressively reduces the work of breathing, improves lung function, and raises oxygen levels.13PubMed. Optimum support by high-flow nasal cannula in acute hypoxemic respiratory failure: effects of increasing flow rates For many patients, this keeps them off a ventilator entirely. For others, it buys time while clinicians figure out the underlying cause.
The clinical challenge is identifying who is improving on high-flow oxygen and who is about to deteriorate. A tool called the ROX index has been developed for this purpose. It combines the SpO2/FiO2 ratio with the respiratory rate into a single number. A higher ROX index suggests the patient is coping well; a low or falling value signals trouble. In patients with acute hypoxemic respiratory failure from pneumonia, the ROX index at 24 hours was a strong predictor of whether high-flow therapy would succeed, with a cutoff value around 5.35 identifying patients likely to do well.14Pulmonary Pharmacology & Therapeutics. Usefulness of ROX index to predict success of high-flow nasal cannula in acute respiratory failure due to SARS-CoV-2 pneumonia The index has also been validated in patients receiving non-invasive ventilation, where its predictive accuracy improved with time: the best discrimination between success and failure came at the 24-hour mark.15PubMed Central. Prediction of noninvasive ventilation failure using the ROX index in patients with de novo acute respiratory failure
More recent work has extended the ROX index beyond its original pneumonia population, testing it in patients with non-pneumonia causes of acute respiratory failure. The index showed moderate ability to discriminate early, suggesting it may be a broadly useful bedside screening tool rather than one limited to a single diagnosis.16PLOS ONE. Expanding the utility of the ROX index among patients with acute hypoxemic respiratory failure
Mortality and How Severity Affects It
Acute respiratory failure carries substantial mortality, and the risk scales directly with how badly oxygenation is impaired. A large registry study spanning nearly two decades in Australian and New Zealand ICUs examined over 800,000 patients who had acute hypoxemic respiratory failure within 24 hours of ICU admission. Among those with mild impairment, in-hospital mortality was about 8%. For moderate impairment, it rose to roughly 14%. And for severe cases, mortality reached approximately 30%.17PubMed Central. Epidemiology of acute hypoxaemic respiratory failure in Australian and New Zealand intensive care units during 2005-2022. A binational, registry-based study Mortality accelerated sharply once the PaO2/FiO2 ratio dropped below 200, a threshold that corresponds to moderate ARDS under the Berlin definition.
For ARDS specifically, the large 50-country LUNG SAFE study reported unadjusted hospital mortality around 40%.18JAMA. Epidemiology, Patterns of Care, and Mortality for Patients With Acute Respiratory Distress Syndrome in Intensive Care Units in 50 Countries That number has been stubbornly resistant to improvement despite decades of ventilator research, though it has come down from the even higher rates seen before lung-protective ventilation strategies became standard. The gap between the mortality of mild acute respiratory failure and that of full-blown ARDS highlights why early detection and escalation of care matter so much.
Pediatric Considerations
Defining acute respiratory failure in children isn’t as straightforward as applying the adult criteria with smaller numbers. Children present unique challenges. Arterial blood gas sampling is used less often in pediatric ICUs because the procedure is painful and technically difficult in small patients. Pulse oximetry has largely taken its place. This means that definitions built around PaO2 measurements can miss cases in children or selectively identify only the sickest ones who happen to get an arterial line placed for other reasons.19PubMed Central. Pediatric Acute Respiratory Distress Syndrome: Consensus Recommendations From the Pediatric Acute Lung Injury Consensus Conference
There is also greater variability in how children are ventilated compared with adults, which makes the PaO2/FiO2 ratio less reliable as a severity marker. The ratio changes depending on how much pressure the ventilator delivers, and pediatric practice varies more across institutions. For this reason, pediatric specialists have adopted alternative metrics, including the oxygenation index and the oxygen saturation index, both of which incorporate the ventilator’s mean airway pressure into the calculation. These indices give a more standardized picture of how hard it is to oxygenate a child’s blood, accounting for how much mechanical support is being thrown at the problem.20PubMed Central. Pediatric Acute Respiratory Distress Syndrome: Consensus Recommendations From the Pediatric Acute Lung Injury Consensus Conference The pediatric ARDS consensus conference formalized these alternative criteria, creating a definition specifically tailored to how children are monitored and treated in practice.
Pulse Oximetry Bias and Skin Pigmentation
One of the more troubling findings in recent years is that pulse oximeters don’t work equally well across all skin tones. A systematic review of 42 studies found consistent evidence that pulse oximeters overestimate oxygen saturation in people with darker skin, particularly at lower oxygen levels where accuracy matters most.21PubMed Central. Do Differences in Skin Pigmentation Affect Detection of Hypoxemia by Pulse Oximetry: A Systematic Review of the Literature In practical terms, the device may display a reassuring number while the actual oxygen level in the blood is significantly lower. This means a patient with darker skin could meet the clinical criteria for acute respiratory failure on an arterial blood gas but appear stable on pulse oximetry.
The implications ripple through everything discussed above. If the global ARDS definition increasingly relies on pulse oximetry-based thresholds to make the diagnosis accessible worldwide, and pulse oximeters systematically undercount hypoxemia in certain populations, then those populations may receive delayed treatment. This isn’t a theoretical concern: studies during the COVID-19 pandemic documented cases where patients with darker skin had occult hypoxemia detected only after arterial blood gas testing revealed saturations far below what the oximeter had been displaying. The technology is being actively reexamined, with calls for improved device calibration and standardized methods for assessing skin pigmentation in clinical research.
Emerging Research on Inflammatory Subphenotypes
The traditional definition of acute respiratory failure treats it as a single entity defined by gas exchange thresholds. But research is increasingly showing that patients who meet the same blood gas criteria may have very different underlying biology. Work on ARDS has identified at least two inflammatory subphenotypes: a hyperinflammatory type with higher levels of circulating inflammatory markers and worse outcomes, and a hypoinflammatory type with a more modest immune response and better survival. A study of mechanically ventilated patients found that this two-subphenotype framework applies beyond ARDS alone, extending to the broader population of patients with acute respiratory failure regardless of their specific diagnosis.22PubMed Central. Biomarker-Based Classification of Patients With Acute Respiratory Failure Into Inflammatory Subphenotypes: A Single-Center Exploratory Study
This matters because it suggests the definition of acute respiratory failure, as it currently stands, lumps together patients who may need fundamentally different treatments. A patient in the hyperinflammatory subphenotype might benefit from aggressive anti-inflammatory therapy, while the same treatment could be unhelpful or even harmful in the hypoinflammatory group. Clinical trials that mix both groups together may wash out real treatment effects. The field is still years away from routinely subtyping patients at the bedside, but the research direction is clear: the gas exchange thresholds that define the syndrome are just the starting point, not the full picture.